Weekly until day +200, monthly thereafter, starting with the first referred sample at day +21; inclusion criteria: at least 7 PB or BM samples until day +100 and 5 additional samples until day +200

b Confirmation of recipient signal >1% (within one week)

c Starting dose of CD3\(^+\) cells/kg, 2.5 \times 10^4 (MMFD), 1 \times 10^5 (MUD), 1 \times 10^6 (MSD) in patients without or with aGvHD not exceeding grade I aGvHD

d Increase of CD3\(^+\) cells/kg, same (MMFD), doubling (MUD and MSD) in patients without aGvHD exceeding grade I aGvHD

Abbreviations: CC, complete chimerism; (de)MC, (decreasing) mixed chimerism, IS, immunosuppression (CSA, cyclosporine A and MMF, mycophenolate mofetil), DLI, donor lymphocyte infusion, MMFD, haploidentical donor, MUD, matched unrelated donor, MSD, matched sibling donor, aGVHD, acute graft-versus-host disease; rips, relapse; CR, complete remission.